Contact For patients
Coloplast Professional
Ostomy

All content

All content

E-learning

All e-learnings

Articles

All articles

Webinars on demand

All webinars on demand

Patient cases

All patient cases

All evidence

All evidence

Short reads

All shortreads

All ostomy products

Product catalogue

Patient resources

All patient resources Educational videos Instructions for use Assessment

Tools for professionals

All tools for professionals Fit Tool

All events

Event calendar

All campaigns

All campaigns
Bladder

Videos

All videos

Articles

All articles

Webinars on demand

All webinars on demand

E-learning

All e-learnings

Patient resources

Instructions for use Tools

Tools for professionals

All tools UTI Risk Factors Model

Clinical evidence

All clinical evidence

All continence products

Product catalogue

All campaigns

All campaigns
Bowel

Patient resources

All instructions

Tools for professionals

All tools for professionals

Videos

All videos

E-learning

All e-learning

Articles

All articles TAI LARS

Webinars on demand

All webinars on demand

Shortreads

All shortreads

Evidence

All evidence

All bowel products

Product catalog
Wound

Conferences

EWMA

Webinar

Surgical Wounds

E-learning

Wound Infections Skin Integrity Leg Ulcers Diabetic Foot Ulcer Pressure Injury Management Pressure Injury Prevention Moist Wound Healing

Podcast

Assess, Prepare and Treat

Workshops

Workshops

How to treat chronic wounds

Wound Care Pathway

How to treat specific wound types

The Wound Type Specific Pathways Surgical wound dehiscence Pressure injury ulcer Malignant wound Skin tear Burn Diabetic foot ulcer Venous leg ulcer

Wound Care knowledge

Stages of wound healing Wound debriment Exudate management The role of the skin Infextion and biofilm Moist wound healing Pressure injury prevention

Tools and guides - Download center

Product selection tool Evidence Cutting guide Wound Pathways Triangle of Wound Assessment

How to use our products

How to apply Gelling Fibers How to apply Foam Dressings How to apply SIlicone Foam Dressings

Featured products

Comfeel® Alprep® Pad Biatain® Silicone Fit Biatain® Silicone Biatain® Fiber Ag Biatain® Superabsorber

Product catalog

Painful wounds Infected wounds Non-infected wounds Heavy exuding wounds Medium exuding wounds Exuding wounds Dry wounds

Type of dressings

Hydrocolloid dressings Contact layer Silver dressings Foam dressings Silicone foam dressings Gelling fibre dressings

Get support

Get support
Interventional Urology

Erectile restoration

Clinical and Economic Evidence Clinical Learning Webinars How to eLearning

Male continence

Clinical and Economic Evidence Clinical Learning eLearning

Testicular replacement

Clinical and Economic Evidence Clinical Learning How To eLearning

More on men's health

eLearning Podcasts Event Calendar

Female Continence

Clinical and Economic Evidence Clinical Learning Webinars How To eLearning

Pelvic Floor Reconstruction

Clinical and Economic Evidence Clinical Learning How To eLearning

eLearning

All eLearning

Events

Event Calendar

Stone Management

Clinical and Economic Evidence Coloplast TFL Drive Laser & Fibers Clinical Learning eLearning

BPH

Clinical and Economic Evidence Clinical Learning eLearning

Soft Tissue Management

Clinical Learning eLearning

Events

Event Calendar
Log in
Coloplast Professional
New Mobile navigation Shopping basket Shopping basket Shopping basket Print Icon Icon / delete Temp Info

This site is intended for Healthcare Professionals only. The site content is intended for informational- and educational purposes and may not be appropriate for all jurisdictions. Coloplast does not provide medical advice. Responsibility for patient care resides with the health care professional. For detailed device information on products presented, including instructions for use, contraindications, effects, precautions and warnings, please consult the product’s Instructions for Use (IFU) prior to use.

Yes, I am a Healthcare Professional No, I am not a Healthcare Professional

Take a shorter way to wound healing

By following the steps in this pathway, you can provide an optimal healing environment for malignant wounds and reduce the risk of complications that could lead to delayed healing or worse.


Any advice included here needs to work in conjunction with your local protocols and your individual scope of practice.

This article is based on the book A pathway for treating a person with a: Malignant wound.

What is a malignant wound and what does it look like?

Malignant wounds are predominantly cancer related, however, people at the end of life may present with malignant fungating wounds that are noncancerous in origin.1 Malignant wounds are challenging because of their typical characteristics – excessive leakage/exudate, bleeding, pain, malodour and disfigurement.2 Malignant wounds are also referred to as tumour necrosis, a fungating wound, ulcerating cancerous wound, malignant cutaneous wound, fungating wound, marjolin’s ulcers or malignant lesions. Malignant wounds are often end-of-life wounds that have a low potential for healing, making them challenging to treat and requiring a focus on symptomatic care, with the aim to improve quality of life (QoL).1

This pathway is focused on treating a person with a non-healing malignant wound. Patients with malignancy who have a wound of another ethiology should be treated using the pathway that best matches the wound’s originating ethiology. For example, for a patient with a surgical wound where a malignant tumour has been surgically removed please follow the Surgical Wounds Pathway or if a patient has a venous leg ulcer that turns malignant, but is deemed healable, it is best to follow the Venous Leg Ulcer (VLU) Pathway.

Squamous Cell Carcinoma

Basal Cell Carcinoma

Malignant Wounds can generate excessive suffering for the patient and their caregivers due to:3

  • Malodour
  • Excessive bleeding
  • Pain
  • Highly exudating
  • Often disfiguring


Patients and their caregivers/families often require psychological, spiritual and emotional support along with physical care. The aim of malignant wound management is to reduce the devastating impact the wound has on the individual, their family and their care team, whilst acknowledging the potential for new wounds to develop as the carcinoma escalates or pressure injury/ulcers develop as the skin fails.1

How to assess a malignant wound

➔ Conduct a holistic patient assessment with a focus on patient quality of life, social and family support/environment.



➔ Conduct a wound assessment using a validated assessment tool, with the following special considerations:

  • Watch for tunnelling or undermining.
  • Assess odour, from the patient’s perspective, which can be caused by infection, necrotic tissue or exudate.
  • Amount and type of exudate.
  • Percentage of devitalised tissue.
  • State of surrounding skin.
  • Watch for bleeding and potential for haemorrhage.
  • Effects of location (obstruction of airways, near major arteries, restriction of movement, restriction of eating or basic body functions, etc.).

Conduct a pain assessment and complete physical exam

➔ Conduct a detailed pain assessment to determine the nature and type of pain, duration, severity and impact of daily living, etc. using a validated pain assessment tool.



➔ Include a complete physical exam to check for other injuries/complications (i.e. pressure injuries, skin failure, etc.), including a nutritional assessment as patients with malignant fungating wounds often have significant problems with appetite due to odour.

Remember

ALWAYS take the patient’s goals of care into account. With fungating malignant wounds, patient and caregiver’s primary concerns may not be wound treatment but other issues such as odour, pain and mobility restrictions/activities of living.

➔ Examples of patient care goals

  • Be able to visit with family and friends (i.e. clarity of thought and odour control).
  • Live to see birth of grandchild (life extension).
  • Being able to attend a family wedding (mobility).
  • No pain.
  • Etc.

Keep in mind

1. Schedule regular holistic patient and wound reassessments based on the patient’s changing condition and situation. 


  • Malignant wounds can expand and deteriorate rapidly and require frequent re-evaluation.4
  • Complete a full body re-assessment to identify new wounds that may develop, except in the case of advanced end-of-life stages where it may not be appropriate to disturb the patient.
  • The needs of the patient, overall health and patient and family care goals may also change rapidly over the course of treatment and need to be reviewed at each re-assessment.
  • Amending actions taken and reprioritising the care model may be necessary on multiple occasions, as the patient becomes weaker and less able to care for themselves.


2. All treatments should be patient driven. It is also important to ask the patient’s permission at each visit before conducting assessments, change dressings etc.

How to develop a treatment and care plan

➔ Management of malignant wounds is complex and requires a multidisciplinary approach to care. 



➔ Putting together a multidisciplinary/integrated care team is critical. 



➔ The patient and their family/caregivers must be considered full and active members of the care team. 



➔ The team should include everyone with a role in the patient’s clinical, psychological and spiritual care.

Keep in mind

When putting together a multidisciplinary care team, flexibility is key. Additional team members may be required as the patient progresses and new specialised skills are needed, i.e. pain management specialist, hospice care, etc.

➔ Developing treatment goals

  • Achieving realistic, patient and family-centred measurable goals are the cornerstone of effective care.5
  • Treatment goals must be patient driven, help alleviate social isolation and manage pain. It is critical that clinicians ask the patient before undertaking any treatment or assessment and respect the patient’s decision-making.
  • Patient and family centered care (PFCC) is increasingly linked to improved communication, care quality, and patient decision making.6
  • Patient centred care involves understanding the patient as a person, the patient-healthcare professional relationship, and coordination of care across the healthcare system.7



➔ SMART goals

SMART goals

➔ Treatment planning


  • The treatment plan must be in keeping with the care goals of the patient and their family, which may change over time.4
  • Overall goals should include patient comfort, confidence and sense of wellbeing, prevent social isolation and maintain or improve overall QoL.8
  • Pain management is a critical part of the treatment planning. If pain is not being adequately managed refer.
    • Patient reported pain can include pain due to the underlying condition and specific pain related to the wound site.
    • It is important that a distinction be made between pain caused by stimulation of nerve endings (nociceptive pain), pain caused by nerve dysfunction (neuropathic pain) and pain caused by treatments or dressing changes as they all require different treatments.2,9
    • Pain experienced during dressing changes can be mitigated by advising patients to take their oral medications 45 minutes prior to the nursing visit to ensure the pain medication is at full strength prior to any wound care treatments, or by using a “booster” dose of analgesia prior to treatment. Some studies have also demonstrated a positive effect from the use of topical opioids applied directly to the wound bed.2
    • A pain specialist can help tailor the care to suit the evolving needs of the patient.2,4,10
  • Pruritus or itchy skin can be a side effect of the tumour or of the treatment. Moisturisers, use of neutral soaps, topical anesthetics, localised temperature control, cortisone and antihistamines may help.10
  • Treatment and control of exudate, odour and bleeding are often of immediate importance to optimise patient quality of life.
    • Malodour is recognised as having a major physical and psychological impact on patients and families/caregivers. Determining the cause of the malodour can help in developing a realistic management plan.11
    • There are some reports of success using off-label treatments such as: charcoal dressings, administration of chlorophyll tablets, use of antibiotics, silver dressings, medical honey, sugar, green tea bags and NPWT palliative therapies.
    • There is some agreement that metronidazole gel administered topically and the use of oral metronidazole can reduce odour.
    • Other typical strategies to control odour include

                    -  Use of aromatherapies (some scents may cause nausea for patients. A trial- and error approach to                                               determining which if any scents help may be required).

                    -   Keeping room well ventilated. 


                    -   Kitty litter under the bed. 


    • For all odour reducing dressings, follow manufacturers’ instructions closely to ensure the most effective outcomes.



➔ WHO Analgesic Ladder

WHO Analgesic Ladder. *Adjuvants can be used along any step of the ladder, these may include antidepressants, anticonvulsants, corticosteroids and anxiolytics.

Keep in mind

1. Many treatments for these patients lack higher level evidence due to the nature of this patient population. Often a trial-and-error approach to reducing symptoms is required to find the solution that works best for the patient and family caregivers.


2. Patient and family/caregiver education is paramount. Understanding expected disease progression, effective supported self-care options and preparing for contingencies (i.e. haemorrhages) allow patients and families/carers to be actively and appropriately involved in treatment planning.

How to manage a malignant wound

➔ Cleansing & Debridement: 


  • Therapeutic cleansing/irrigation and debridement may be necessary to remove necrotic tissue and reduce odour.
  • Self showering is a viable cleansing technique based on the patient’s abilities and preferences.
  • Aggressive or sharp debridement is not recommended on malignant wounds. Autolytic debridement can be achieved using hydrating dressings or honey.5 Debulking tumours to remove necrotic tissue and reduce odour should only be done by a specialist.
  • Mild wound cleansing is recommended to reduce the incidence of bleeding. Use of potable water, saline or mild antiseptic solutions at room or body temperature are recommended. Therapeutic irrigation and wound cleansing may not be appropriate if deep tunnelling is present.5

Basal Cell Carcinoma

Breast carcinoma

Keep in mind

1. Decisions around therapeutic cleansing and debridement should always take into account patient comfort and care goals. Ask the patient if it is OK to cleanse the wound. If the patient declines, explain the benefits of the treatment, but if the patient does not want the treatment respect his/her wishes.



2. Avoid unnecessary manipulation of the wound, especially for patients with malignant end-of-life wounds

➔ Infection management


  • Only swab if you are planning to treat for infection and where it is necessary to control bacteria where resistant organisms require special infection control measurements.12
  • Controlling bacteria can decrease exudate, pain and odour and help stabilise a non healing wound.13
  • If unexpected infection is persistent, spreading or if systemic infection is suspected refer.

Keep in mind

Localised inflammatory effects of the malignant wound may have many of the same characteristics as infection, such as appearing red, inflamed and warm to the touch.

How to choose dressing and additional therapy

➔ Dressing choice should always take into account current treatment and procedures that may impact dressing type and change frequency, such as radiotherapy. 



➔ A dressing should manage exudate, prevent infection, protect periwound skin, allow the patient maximum mobility, comfort and security and be non-traumatic on application and removal. 



➔ Non-adherent soft silicone dressings have been shown to cause less pain upon removal.2

➔ Choose a dressing that:

  • Is comfortable and allows patient maximum mobility.
  • Is convenient for patient and caregiver.
  • Has a long wear time, to reduce painful dressing changes.
  • Is non traumatic on application and removal.Absorbs excess exudate, bleeding and protects periwound skin. 


• Reduces infection risk and odour. 



➔ Avoid the use of petroleum impregnated dressings and occlusive hydrocolloid dressings in fungating wounds.5

Remember

1. It is important to ask the patient’s permission at each visit before conducting a dressing change.
2. Avoid MARSI by using non-adhesive dressings and careful dressing removal.

➔ Malignant wounds are often highly exudating and irregular in size and shape, which makes them difficult to dress and may require an unorthodox approach. A multiple layered dressing approach may be required. Dressing selection should be based on patient needs and preferences and local policy/protocol/formularies. The following chart (see below) breaks down some of the basic theory around dressing types and how they can help manage symptoms for patients with malignant fungating wounds.

Be aware

If patient is not responding to standard care, consider referral for adjunct therapies such as: 


  • Surgery
  • Radiotherapy
  • Hormone therapy
  • Electrochemotherapy (TENS)
  • Laser therapy
  • Chemotherapy

Dressing options for different symptoms

Monitor patient's progress towards care goals

➔ Care must be flexible and focused on the patient’s priorities, as well as management and control of symptoms. 



➔ Assess progress towards care goals and acknowledge that the patient’s goals may change as their condition progresses. 



➔ Taking photos of the wound at dressing changes can help assess progression and will allow other members of the care team to “see the wound” without disturbing the patient. Always ask patient permission before taking the photo and also ask patient if they would like to see the image. 



➔ Monitor environment of care and openly discuss care options with patient and family/caregivers.

Remember

The patient should ALWAYS drive decision-making.

➔ Patient and care giver education and communication:


  • Malignant wound care must always focus on the needs and wishes of the patient.
  • Continuous open communication between all members of the multidisciplinary team, the patient and the patient’s family/caregivers is crucial to ensure effective coordinated care and to manage expectations.
  • Clinical and psychological support for the patient and their family/ caregivers should be part of every interaction with the patient.
  • Preparing the patient and family/caregivers for future stages of care is important (i.e. if wound is near a major artery and there is a possibility of a large or fatal bleed, suggest keeping dark towels on hand to decrease the stress and anxiety from the sight of blood).
  • Providing written instructions to patients and families will often help with information retention.
  • Connecting patients and family/caregivers to community resources can often assist in education and communication efforts and offer additional support.



➔ Caregiver support


  • Clinicians who treat patients with malignant wounds and end-of-lifewounds often face complex challenges of care and additional factors such as moral distress, burnout, compassion fatigue and death anxiety.14
  • Clinician self-care should be prioritised and include extended supervision, reflective practice, access to on-the-spot debriefs, and other support services.
  • Patients found that they felt isolated and cut off by nurses who struggled to acknowledge their own distress.8

When to refer or contact a specialist

  • If pain is not adequately controlled.
  • If unexpected infection is spreading or not adequately controlled. 
  • When alternative therapies, debulking or sharp debridement are necessary. 
  • If episodes of brisk hemorrhage, or uncontrolled bleeding occur.
  • If bone or organs become exposed. Sudden changes in overall health or condition, beyond the expected patient trajectory.
  • For adjunct therapies, such as palliative radiation.

Glossary of malignant wound terms

Malignant Wound

– A cancerous lesion involving the skin, which is open and may be draining. The lesion may be a result of a primary cancer, or a metastasis to the skin from local spread or local invasion. It may take the form of a cavity, an open area on the surface of the skin, skin nodules, or a nodular growth extending from the surface of the skin.12

End-Of-Life

– Sibbald (2009)15 defines end of life as a phase of life when a person is living with an illness that will often deteriorate and eventually cause death.

Fungating Wound

– when a tumour that is growing under the skin breaks through the skin’s surface and creates a wound. As the cancer grows, it can block and damage blood vessels, reducing oxygen supply to the surrounding skin and tissue causing necrosis.

Kennedy Terminal Ulcer (KTU)

– an unavoidable skin breakdown which occurs in some patients as part of the dying process.

MARSI

– Medical Adhesive Related Skin Injury most often caused by the use of adhesives or the aggressive removal of dressings.

Marjolin’s Ulcer

– a cutaneous malignancy that forms in the area of previously injured skin, burn scars, and chronic wounds.

Pruritus

– refers to itchy skin and can have cutaneous, neuropathic, neurogenic, or psychogenic origins.

Tunnelling and Undermining

– when passages or openings develop under or adjacent to the wound bed or there is erosion under the wound edges. Both tunnelling and undermining create cavities within the wound bed where exudate can pool and cause infection.

For a glossary of general wound care terms consult The Wound Care Pathway:

The Wound Care Pathway: Your 5 step guide to wound healing

The Wound Care Pathway: Your 5 step guide to wound healing

PDF 6 MB 25 pages
Preview
Coloplast

Product information

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur

Social media

  • Facebook
  • Linkedin

Contact information

  • Coloplast 1800-653-317
  • Coloplast Mon - Thur -9 am - 5 pm
    Fri 9 am - 4 pm
  • Coloplast xxx@coloplast.com

Product information

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur

Social media

  • Facebook
  • Linkedin

Contact information

  • Coloplast 1800-653-317
  • Coloplast Mon - Thur -9 am - 5 pm
    Fri 9 am - 4 pm
  • Coloplast xxx@coloplast.com
Coloplast Group Holtedam 1 3050Humlebaek Denmark
  • Cookie policy
  • Legal Aspects
  • Privacy Notice
  • Coloplast products - instructions for use
  • Accessibility
  • Cookie Settings